Fares Yared, MD, MSc, MPH

Thank you to esteemed faculty, @shelleyhallmd, Dr. Rachel Garcia, Andrea Wallace, MSN, FNP-C, HF-Cert, FHFSA, and @RichaGuptaMD, for sharing their real-world experience and invaluable insights on #Barostim, and to the #HFSA2025 attendees for contributing to the engaging discussions this afternoon.

@IbrahimAlameh @AUBMC_Official @mainlinehealth Best of luck!!

Cardiology fellowship application ✅ A journey of growth guided by inspiring mentors, meaningful patients, and two training homes I’m proud of: @AUBMC_Official 🇱🇧 and @mainlinehealth 🇺🇸 Grateful. Determined. Ready. #FellowshipMatch #Match2026 #CardioTwitter #CardiologyFellowship

We’re pleased to announce that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim implant procedure as part of the New Technology Ambulatory Payment Classification (APC) 1580, with an associated payment of approximately $45,000 for procedures performed in the outpatient setting. “We appreciate CMS’ proposal to keep Barostim in APC 1580, ensuring appropriate payment for the Barostim implant procedure,” said Kevin Hykes, President and CEO of CVRx. “These reimbursement updates, along with the favorable proposed payment levels included in the recently released physician fee schedule, allow us to continue our progress toward expanding access to Barostim for patients suffering from heart failure with reduced ejection fraction, which we believe will help support its broader market adoption and long-term growth.” Read the full press release: barost.im/4lvSWZp

Happening tomorrow! Don't miss our webinar where Philip Adamson, MD, Melissa Wendell, FNP-BC, and Michael Gajewski, AGACNP will explore the APP's critical role in managing #Barostim patients. Discussions will include: -Identifying the right patients -Staging treatment options for HFrEF -Shared decision making -Optimizing clinic workflows 📅 Register now: barost.im/Barostim_JuneA…

We are grateful for the over 75 physicians, nurses, and advanced practice providers who attended our two educational summits over the weekend. Our Friday APP Summit was facilitated by Dr. Manuel Perez-Izquierdo, Melissa Wendell, NP, Andrea Wallace, NP, and Michael Gajewski, NP, who led a dynamic session around appropriate patient selection of #Barostim patients, staging of #heartfailure treatments, and strategies for APPs to become therapy advocates. On Saturday, Dr. Philip Adamson led an in-depth discussion with Drs. Rachel Garcia, Jean Marie Ruddy, @DmitryYaranovMD, and Amarinder Bindra on strategies to integrate Barostim into a cardiology and heart failure program. Speak to your Barostim representative to learn more about upcoming Barostim medical education programs, webinars, and conference symposia.

Enhance your knowledge about #Barostim and its role in #heartfailure management through this #ACCEd virtual course. Take the course to learn about: -The stages of heart failure where Barostim is useful -Patient selection criteria -How Barostim complements guideline-directed medical therapy (GDMT) -The impact of a multidisciplinary team approach in optimizing Barostim for improved patient outcomes in heart failure management Access the course: barost.im/3FEPJXn

“The win-win of this procedure is that it’s low-risk, easy recovery, and produces results. Roughly 90% of our implanted patients reported seeing improvements in their heart failure symptoms. Heart failure medications have survival benefits but don’t give you much quality-of-life improvement. That’s where Barostim can fit in and fill an important gap.” -@RichaGuptaMD Read how Dr. Gupta’s patient, Harold, went from battling sleepless nights and #heartfailure symptoms to regaining his quality of life after receiving #Barostim. barost.im/3SfIw3r

Congratulations to the members of the SWIFT-HF research group on their new publication in Heart Failure Reviews, "Beyond GDMT: Bridging the Therapeutic Gap in Heart Failure".

Kicking off day 2 at #ISHLT2025! Drop by our booth to learn how #Barostim targets the neurohormonal pathway to improve symptoms in patients with #HFrEF. And be sure to join our symposium on Tuesday at 11:45 AM in room 312.

At #ACC25 this year? Make sure to visit us this weekend (Booth #9005) to learn how #Barostim - an innovative device that targets the neurohormonal pathway - can significantly improve exercise capacity and quality of life in patients with #heartfailure beyond GDMT alone.

Beyond thrilled and grateful to join @HopkinsMedicine for my #Dermatology residency! Endless gratitude to my mentors who made this possible. To IMGs: keep pushing! Your goals are within reach. #match2025

@Nina is an inspiration and living testament that with grit, passion, and purpose, anything is possible.

We made the life-changing decision to move to the US, a journey filled with challenges, sacrifices, and uncertainties. There were many variables along the road - but always one constant: Hopkins.

Taking a moment to celebrate a milestone that means the world to us - @Nina matched into Dermatology at Johns Hopkins, one of the most competitive specialties in the US! We are grateful to be here in the US, building a future that once felt like a distant dream!

Attending #ACC25 next weekend? Visit us at booth #9005 to learn about #Barostim - a novel device therapy that targets the neurohormonal pathway to significantly improve #heartfailure symptoms. ISI: barost.im/ISI

New real-world evidence demonstrated large and statistically significant reductions in hospital visits and length of stay in #Barostim patients with #heartfailure and reduced ejection fraction in a recently published study in the @JCardFail.1,2 See the evidence: barost.im/jcf

Check the publication in the Journal of Cardiac Failure: barost.im/jcf Read the press release to learn more: barost.im/42P7Un3 Dive deeper into the data, listen to the Brain-Heart Continuum podcast: lnkd.in/gKH947N5 ISI: barost.im/ISI

Check out this all-payer database analysis of 306 Barostim patients identified showing: • 86% reduction in all-cause hospital visits (p<0.0001) • 84% reduction in cardiovascular hospital visits (p<0.0001) • 85% reduction in heart-failure hospital visits (p<0.0001)

Thanks to @shelleyhallmd for her comprehensive review of #Barostim as a device therapy option to improve #heartfailure symptoms during today's "Current and Emerging Novel Device Therapies" session at #THT2025.

Today we announced our fourth quarter and full year financial results and provided a business outlook for 2025. We are pleased to share these milestones: -Active US implanting centers increased 25% over prior year end -US HF revenue increased 41% over prior year Q4 -Increased worldwide revenue 36% over prior year Q4 "We capped off a very strong 2024 with a solid fourth quarter, which included 41% growth in U.S. heart failure revenue as well the successful achievement of multiple critical reimbursement milestones," said Kevin Hykes, President and CEO of CVRx. "As we look to 2025, we are focused on three key strategic priorities to drive Barostim toward becoming the standard of care – building a world-class sales organization, supporting the development of sustainable Barostim programs to drive deeper utilization, and addressing barriers to adoption. With the organization-wide success we saw in 2024, in combination with our key priorities for 2025, we are well-positioned to drive the continued adoption of Barostim therapy." Learn more: barost.im/4jVyL74